
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune is well-positioned for success with its focus on Precision Medicine and therapeutic and diagnostic products targeting misfolded proteins for neurodegenerative diseases, supported by additional partnerships and a robust pipeline. The company's potential revenue streams, including from its programmed cell death therapeutics, are further bolstered by its competitive advantages in active immunotherapy and its versatile Morphomer platform. While there are technical risks, AC Immune's strong platform, impressive pipeline, and timely offerings make for a positive outlook for the future of the company.
Bears say
AC Immune is likely to experience delays in decisions from partner Takeda due to enrollment in the ACI24 Cohort AD4 of the ABATE trial and the lack of obvious clinical effects for their drug that modifies the course of PD. Additionally, while there have been positive results in terms of reduced levels of protein aggregates, the ultimate impact on motor and cognitive function still needs to be quantified and the ideal target product profile remains uncertain. Overall, AC Immune may struggle to show significant success in their clinical trials and may face challenges with delayed decision-making and uncertainty about their drug's effectiveness.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares